|
|
Article: ArQule Partners ARQ 197 In Asia In Potential $123M Collaboration.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
ArQule Inc. entered a partnership on the lead program from its Cancer Survival Protein modulation program, a deal worth up to $123 million with Kyowa Hakko Kogyo Co. Ltd.
ArQule, of Woburn, Mass., gets $30 million up front in the deal. Kyowa, of Tokyo, gets exclusive rights to the cancer agent ARQ 197 in Japan, China, South Korea and Taiwan.
ARQ 197, a small-molecule, selective inhibitor of the c-Met receptor tyrosine kinase, has been tested in a Phase I trial and is being prepared to move into a Phase II program. ArQule is entitled to up to $93 million in development milestone payments from Kyowa, as well as undisclosed sales ...